Go to main content

Product Details


PONVeridol® is indicated for the prevention and treatment of postoperative nausea and vomiting (PONV) in adults and as a second-line treatment in children (2 to 11 years) and adolescents (12 to 18 years) and for the prevention of morphine derivative-induced nausea and vomiting in adults during postoperative patient-controlled analgesia (PCA).

Drug Facts

Active ingredient: droperidol | Dosage form: solution for injection | Strength: 1.25 mg/ml

Marketing authorisation holder: Amomed Pharma GmbH